Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06083753 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
A Phase 2 study of Relapsing Remitting Multiple Sclerosis, sponsored by Contineum Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 20
- Study locations
NCT06083753: Completed Phase 2 study of Relapsing Remitting Multiple Sclerosis, sponsored by Contineum Therapeutics.
NCT06083753 is a Phase 2 study of Relapsing Remitting Multiple Sclerosis that has completed, run by Contineum Therapeutics. The registered enrollment target is 182 participants, roughly in line with the 195-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06083753, a Phase 2 study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by Contineum Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
Primary Outcome
Number of participants with TEAEs
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PIPE-307 Dose A
- DRUG PIPE-307 Dose B
Study Locations (20)
Texas
- University of Texas Health Science Center at Houston - Houston
- Clinical Trial Network - Houston
- Bhupesh Dihenia, MD, PA - Lubbock
Arizona
- Xenosciences - Phoenix
- Arizona Neuroscience Research, LLC - Phoenix
Florida
- MS and Neuromuscular Center of Excellence - Clearwater
- Aqualane Clinical Research - Naples
New York
- Dent Neurologic Institute - Amherst
- Neurological Associates of Long Island, P.C. - Lake Success
Washington
- Virginia Mason Medical Center - Seattle
- UW Medicine MS Center - Seattle
California
- Alta Bates Summit Medical Center - Berkeley
Colorado
- Colorado Springs Neurological Associates - Colorado Springs
Georgia
- Shepherd Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2025-08-04 |
| Phase | Phase 2 |
What the finished NCT06083753 record still lists
NCT06083753 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 195-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target.
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06083753 names 20 study sites across 14 states, led by Texas, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06083753 about?
NCT06083753 is a clinical study titled "Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis". This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
What is the current status of trial NCT06083753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2023-11-06. Estimated completion is 2025-08-04.
What conditions does trial NCT06083753 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
What interventions are being tested in trial NCT06083753?
The interventions under investigation include: Placebo (DRUG), PIPE-307 Dose A (DRUG), PIPE-307 Dose B (DRUG).
Who is sponsoring clinical trial NCT06083753?
This trial is sponsored by Contineum Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06083753 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06083753's enrollment target sits among peer trials
182 7th of 25 higher than 19 of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
COMPLETED · Phase 2
-
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
COMPLETED · Phase 2
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI